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Background: 
Curcumin has been reported to have anti-inflammatory, antioxidant, antiviral, antifungal, antitumor, and 
antinociceptive activity when administered systemically. We investigated the analgesic efficacy of intrathecal 
curcumin in a rat model of inflammatory pain.
Methods: 
Male Sprague Dawley rats were prepared for intrathecal catheterization. Pain was evoked by injection of 
formalin solution (5%, 50 μl) into the hind paw. Curcumin doses of 62.5, 125, 250, and 500 μg were delivered 
through an intrathecal catheter to examine the flinching responses. The ED50 values (half-maximal effective 
dose) with 95% confidence intervals of curcumin for both phases of the formalin test were calculated from 
the dose-response lines fitted by least-squares linear regression on a log scale.
Results: 
In rats with intrathecal administration of curcumin, the flinching responses were significantly decreased in 
both phases. The slope of the regression line was significantly different from zero only in phase 2, and the 
ED50 value (95% confidence interval) of curcumin was 511.4 μg (23.5−1126.5). There was no apparent 
abnormal behavior following the administration of curcumin.
Conclusions: 
Intrathecal administration of curcumin decreased inflammatory pain in rats, and further investigation to 
elucidate the precise mechanism of spinal action of curcumin is warranted. (Korean J Pain 2012; 25: 1-6)
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INTRODUCTION
Curcumin (1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6- 
heptadiene-3,5-dione) is a major bioactive component of 
turmeric, which has been used as a coloring agent in food. 
It has been used as an herbal medicine for centuries in 
India, China, Japan, and Korea. Recently, curcumin has 
r e c e i v e d  a  g r e a t  d e a l  o f  a t t e n t i o n  f o r  i t s  a n t i - i n f l a m-
matory,  antioxidant,  antiviral,  antifungal,  and  antitumor 
actions [1-4]. In addition, curcumin has been reported to 
have antinociceptive activity when administered systemi-
cally. The analgesic effects of curcumin are thought to be 
exerted by suppression of nitrite, TNF-α, and capsaicin- 
induced TRPV1 activity, and through the descending nora-
drenergic and serotonergic systems, [5-7]. Furthermore, 
c u r c u m i n  h a s  b e e n  s h o w n  t o  e x h i b i t  a n t i - i n f l a m m a t o r y 
activity by means of inhibition of a number of different 
mediators  including  phospholipase,  lipoxygenase,  cyclo-
oxygenase-2, leukotrienes, thromboxane, prostaglandins, 
a n d  n i t r i c  o x i d e  [ 1 , 8 - 1 0 ] .  A s  i n c r e a s e d  s p i n a l  c o r d  e x-
pression  of  these  substances  is  associated  with  pain 
[11-13], we hypothesized that intrathecal administration of 
curcumin may also produce antinociception.
However, neither the effect of intrathecally admini-
stered curcumin nor its spinal mechanism of action has 
been  investigated.  Therefore,  the  purpose  of  this  study 
was to evaluate the analgesic efficacy of intrathecal cur-
cumin in a rat model of inflammatory pain.
MATERIALS  AND  METHODS
The  experimental  protocol  was  approved  by  the 
Institutional Animal Care and Use Committee, Chonnam 
N a t i o n a l  U n i v e r s i t y .  E x p e r i m e n t s  w e r e  c o n d u c t e d  u s i n g  
adult male Sprague Dawley rats weighing 250-300 g. The 
rats were housed in individual cages in a temperature- 
controlled  room (22  ±  0.5
oC) with a 12/12-h light/dark 
cycle.  Food  and  water  were  freely  available.  Intrathecal 
catheterization was performed for drug administration as 
described  previously  [14].  Briefly,  the  rats  were  anes-
thetized with sevoflurane under spontaneous respiration, 
and placed in a stereotaxic head holder. A polyethylene-10 
catheter was inserted through an incision in the atlan-
tooccipital membrane. The catheter was advanced caudally 
8.5 cm from the incision site to the lumbar enlargement 
of the spinal cord. The external end of the catheter was 
tunneled subcutaneously to exit at the top of the head and 
plugged with a piece of steel wire, and the skin was closed 
using 3-0 silk suture. The rats were closely monitored and 
euthanized through a volatile anesthetic overdose if motor 
abnormalities appeared. Normal rats were kept in individual 
cages, and a period of not less than 5 days was allowed 
for each rat to recover from intrathecal catheterization. 
Rats showing apparently normal behavior and weight gain 
were assigned to the experiment.
Curcumin ([1E,6E]-1,7-Bis[4-hydroxy-3-methoxyphenyl]- 
1,6-heptadiene-3,5-dione,  Tocris  Cookson  Ltd.,  Bristol, 
UK) was dissolved in 100% dimethyl sulfoxide (DMSO). The 
drug was administered intrathecally in a 10 μl solution vol-
ume using a hand-driven gear-operated syringe pump, 
followed by an additional 10 μl of vehicle solution to flush 
the catheter. To examine the analgesic efficacy of curcu-
min in the formalin test, curcumin (62.5, 125, 250, 500 μg) 
was administered intrathecally to 5 rats in each group 10 
min prior to the formalin test. Doses of curcumin were de-
termined by the maximum solubility of the drug and for 
approximately equal spacing on the log scale.
On the day of the experiment, rats were acclimatized 
in a restraint cylinder for 15-20 min, and were randomly 
allocated into drug-treatment groups, each receiving one 
of the doses of curcumin, or the control group, receiving 
D M S O  o n l y.  Ea c h r a t  w a s  u se d  o n l y  o n c e  a n d  t h e r e-
searcher who tested the drugs was blind to the drug admi-
nistered to each animal. The formalin test was performed 
by subcutaneously injecting 50 μl of 5% formalin solution 
into the plantar surface of the left hind paw using a 30 
gauge needle. The formalin injection evoked a character-
istic spontaneous flinching behavior, and thus the pain be-
havior was quantified by periodically counting the number 
of flinches of the injected paw. The number of flinches was 
counted for 1 min periods from 1 to 2 min and 5 to 6 min, 
and every 5 min thereafter, up to 60 min. The observed 
responses  appeared  biphasically  and  were  divided  into 
phase 1 (0-9 min) and phase 2 (10-60 min). After the entire 
observation period, the rats were euthanized with an over-
dose of volatile anesthetic.
The behavioral effects of curcumin were evaluated in 
an additional group of rats (n = 5). Motor function was 
assessed f o r 6 0  m in  a f t e r in t r a t h ec a l a d m i n is t r a t i o n  o f 
500  μg curcumin. The righting reflex was examined by 
placing  the  rat  horizontally  with  its  back  on  the  table, 
which normally produces an immediate coordinated twist-YK Han, et al / Antinociceptive Effect of Intrathecal Curcumin 3
Fig. 1. Time course of intrathecal curcumin on flinching 
response during the formalin test. Curcumin was admini-
stered 10 min before the formalin injection. Data are 
presented as the mean of the number of flinches ± SEM 
of 5 rats at each time point.
Fig. 2. Dose-response curves of intrathecal curcumin on flinching response during phase 1 (A) and phase 2 (B) in the formalin
test. Curcumin was administered 10 min before the formalin injection. Data are presented as the percentage of control.
Each line represents mean ± SEM of 5 rats. Compared with control, *P ＜ 0.05.
ing of the body to achieve an upright position. The plac-
ing/stepping reflex was evoked by drawing the dorsum of 
either hind paw across the edge of the table, a stimulus 
which causes normal rats to try to put their paws forward 
into a position for walking. Pinna and corneal reflexes were 
evaluated by stimulating the ear canal or the cornea with 
a  paper  string.  Normal  rats  spontaneously  jerked  their 
heads or blinked, respectively.
Data are expressed as mean ± SEM. The time-response 
data of the behavior evoked by formalin are presented as 
the number of flinches. The dose-response data are pre-
sented as a percentage of the control for each phase:
% of control =
T otal number of flinches with drug in phase 1 (2)
× 100%
Total number of flinches of control in phase 1 (2)
Dose-response data were analyzed using the Kruskal- 
Wallis  test  and  Mann-Whitney  U  test.  The  ED50 v a l u e s 
(half-maximal effective dose) with 95% confidence inter-
vals of curcumin for both phases of the formalin test were 
calculated from the dose-response lines fitted by least- 
squares linear regression on a log scale [15]. A test to de-
termine whether the effect is dose-dependent was made 
from the F distribution as previously described [15]. A value 
of  P  ＜  0 . 0 5  w a s  c o n s i d e r e d  t o  i n d i c a t e  s t a t i s t i c a l  
significance.
RESULTS
Subcutaneous injection of formalin into the hind paw 
p r o d u c e d  a  b i p h a s i c  f l i n c h i n g  r e s p o n s e ,  w i t h  a n  e a r l y  
(phase 1) response lasting 5-10 min, and after a quiescent 
interval of 5-10 min, a subsequent late (phase 2) response 
up to 60 min. Fig. 1 shows the time course and dose-re-
sponse data of intrathecal curcumin, administered 10 min 
before formalin injection, in the formalin test. In the con-
t r o l  gr o u p  w i t h in t r a t h ec a l i n j ec t i o n o f D M S O ,  t h e t o t a l 
n um ber of flinches w as (mean ± SEM) 28 ± 5 d uring 
phase 1 and 220 ± 15 during phase 2. Fig. 2A and 2B show 
the  dose-response  curves  of  intrathecal  curcumin  on 4 Korean J Pain Vol. 25, No. 1, 2012
flinching response during both phases of the formalin test. 
I n  r a t s  w i t h  i n t r a t h e c a l  a d m i n i s t r a t i o n  o f  c u r c u m i n ,  t h e 
number of flinching responses was significantly decreased 
to 35-38% of the control group during phase 1 of the for-
malin test (P ＜ 0.05), but the extent of change was not 
statistically different over the range of administered doses 
(P ＞ 0.05, determined by Kruskal-Wallis test, Fig. 2A). 
D u r i n g  p h a s e  2 ,  i n t r a t h e c a l  d e l i v e r y  o f  c u r c u m i n  s u p -
pressed the flinching response up to 49% of control, and 
the extent of change was statistically different over the 
range of doses (P ＜ 0.05, determined by Kruskal-Wallis 
test, Fig. 2B).
The calculated F values for linear regression of an-
algesia on log dose of curcumin were 0.036 and 5.902, for 
phases 1 and 2, respectively. The F value of phase 2 ex-
ceeds the tabular F = 4.41 based on the degrees of free-
dom for this study (1, 18) for P ＜ 0.05. These data indicate 
that the slope of the regression line was significantly dif-
f e r e n t  f r o m  z e r o  o n l y  i n  p h a s e  2  a n d  t h a t  t h e  c u r c u-
min-produced analgesia was dose-dependent in phase 2 
but not phase 1 of the formalin test. Consequently the ED50 
value (95% confidence interval) of curcumin was calculated 
only for phase 2 and was 511.4 μg (23.5-1,126.5).
There was no apparent abnormal behavior in the rats 
following the administration of curcumin.
DISCUSSION
Formalin-induced nociception consists of two different 
nociceptive states, and distinct mechanisms underlie the 
t w o  p h a s e s  o f  b e h a v i o r a l  r e s p o n s e .  A c u t e  n o c i c e p t i o n  
(phase 1) is followed by the facilitated state (phase 2). The 
phase 1 response appears to result from the immediate and 
intensive increase in activity of the primary afferent fibers 
induced by formalin, reflecting an acute pain. On the other 
hand, the phase 2 response may result from the activation 
of wide dynamic range neurons in the dorsal horn, with 
a continuous low level of activity in the primary afferent 
fibers [16]. Therefore, phase 2 represents a facilitated state 
which appears to be a prominent and intensified pain state 
in spite of a decreased level of afferent input. This pain 
model has been utilized as a tool for observing the effects 
of various antinociceptiv e agents on these two types of 
pain at once. 
In the present study, we evaluated the analgesic effect 
o f  c u r c u m i n  a t  t h e  s p i n a l  l e v e l  i n  a  r a t  m o d e l  o f  i n-
flammatory pain. Intrathecally administered curcumin re-
duced the flinching response evoked by formalin injection 
during both phases. Intrathecal curcumin also produced no 
behavioral abnormalities. These findings suggest that cur-
cumin possesses a spinal mechanism of action, and pres-
ent the possibility of curcumin as a novel analgesic agent 
to be delivered in the spinal cord. 
Previous reports have demonstrated analgesic effects 
of systemically administered curcumin in rodent models of 
d i a be t i c  n e ur o p a t h i c  p a in  [5 ],  f o r m a lin - in d u c e d  o r o f a c i a l 
pain [17], capsaicin-induced thermal hyperalgesia [6], and 
chronic constriction  injury-induced neuropathic  pain [7]. 
The mechanisms underlying the analgesic action of sys-
temically administered curcumin have been suggested to 
be associated with suppression of brain nitrite and serum 
tumor necrosis factor α levels [5], antagonistic effects on 
the transient receptor potential vanilloid 1 channel [6], and 
the descending monoamine system coupled with opioid re-
ceptors [7]. Although the spinal analgesic effect of curcu-
min has not been studied, the results of the study of Zhao 
et al. [7] are consistent with the current study. Intrathecal 
but not intracerebroventricular injection of adrenergic or 
serotonergic antagonists blocked the antinociceptive effect 
o f  c u r c u m i n  [ 7 ] .  A s  c u r c u m i n  c a n  p a s s  t h r o u g h  t h e  
blood-brain barrier [18], systemically administered curcu-
min could have enhanced spinal serotonergic or adrenergic 
t r a n s m i s s i o n ,  w h i c h  m i g h t  a l s o  c o n t r i b u t e  t o  t h e  a n t i -
nociception produced by intrathecal administration in the 
current study.
The spinal cord represents a novel site of investigation 
f or pain r esear c h, positioned op tim a ll y f or r egul ati on of 
pain both in respect to convenient external access for drug 
delivery and relative isolation from other parts of the cen-
tral nervous system. Application of spinal delivery of an-
algesic agents in animal studies has contributed to ad-
vances in understanding of the basic science of pain and 
the  analgesic  mechanisms  of  experimental  drugs  [19]. 
Furthermore, the establishment of intrathecal drug admin-
istration methods in humans has provided a new pain relief 
option for patients suffering from chronic intractable pain 
refractory to systemically administered analgesics [20]. As 
the spinal cord neurons are not known to regenerate, de-
v e l o p m e n t  o f  n o v e l  c o m p o u n d s  f o r  s p i n a l  d e l i v e r y  m u s t  
pass particularly strict screening tests before trials in hu-
mans [19]. Although curcumin has been shown to be safe 
in general, it has been demonstrated to cause some gastric YK Han, et al / Antinociceptive Effect of Intrathecal Curcumin 5
irritation in humans [21] and hepatotoxicity in rodents at 
high doses [22,23]. The findings in the current study may 
therefore raise the possibility of curcumin as a novel an-
algesic for spinal delivery, reducing the adverse side effects 
of systemic administration and thus providing therapeutic 
benefit in some patients, and further investigation is war-
ranted to elucidate its precise mechanism of spinal action.
There are some limitations to this study. The mecha-
nisms of the observed curcumin-produced analgesia were 
not elucidated and remain to be further examined. In addi-
tion, the differential effects of intrathecal curcumin on the 
acute and facilitated states should be explored in a future 
study.
In conclusion, intrathecal administration of curcumin 
decreased inflammatory pain in rats, and further inves-
tigation is warranted to elucidate the precise mechanism 
of spinal action of curcumin.
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